Elena Kulagina

Dr. Elena Kulagina

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2012 in Bioscience, Biotechnology, and Biochemistry
Verified
Journal Article
Closed access
EKElena Kulagina
Elena Kulagina
BEBoris A. Efimov
Boris A. Efimov
PMPhillipp Y. Maximov
Phillipp Y. Maximov
LKLyudmila I. Kafarskaia
Lyudmila I. Kafarskaia
ACAndrei Viktorovich Chaplin
Andrei Viktorovich Chaplin
ASAndrey N Shkoporov
Andrey N Shkoporov
A study of species distribution of numerically predominant Bacteroidales order isolates in feces of healthy people aged 1-33 years was accomplished using a combination of amplified ribosomal DNA restriction analysis (ARDRA) and 16S ribosomal DNA (rDNA) sequencing. It was found that the majority of isolates in all age groups belonged to species B. xylanisolvens, B. vulgatus, and B. uniformis. Members of genera Alistipes, Parabacteroides, Odoribacter, Barnesiella, and Prevotella were also detected frequently.

23 March 2008 in Bioscience, Biotechnology, and Biochemistry
Verified
Journal Article
Closed access
ASAndrey N Shkoporov
Andrey N Shkoporov
EKEkaterina V. Khokhlova
Ekaterina V. Khokhlova
EKElena Kulagina
Elena Kulagina
VSVladimir V. Smeianov
Vladimir V. Smeianov
LKLyudmila I. Kafarskaia
Lyudmila I. Kafarskaia
BEBoris A. Efimov
Boris A. Efimov
Bifidobacteria and Bacteroides-like bacteria are strictly anaerobic nonpathogenic members of human intestinal microflora. Here we describe an analysis of the species and subspecies composition of these bacterial populations in healthy children using a combination of culture and molecular methods at two different time points. It was found that B. bifidum and B. longum are the most common dominant taxons in infants aged between 8 and 16 months. The majority of the infants carried several dominant Bifidobacterium strains belonging to different species. Examination of the dominant bifidoflora in some of these children after a 5-year period showed major shifts in both species and strain composition, but the dominant strains remained unchanged in two children. The majority of dominant Bacteroides-like isolates belonged to species B. vulgatus and B. uniformis, but members of genera Alistipes and Barnesiella were common too. In addition, a novel approach to species identification of Bacteroidales order bacteria using amplified ribosomal DNA restriction analysis (ARDRA) is described.

20 January 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
AUAnastasia Ushtanit
Anastasia Ushtanit
EKElena Kulagina
Elena Kulagina
YMYulia Mikhailova
Yulia Mikhailova
MMMarina Makarova
Marina Makarova
SSSvetlana Safonova
Svetlana Safonova
Danila ZimenkovDanila Zimenkov
Danila Zimenkov
Background: Ethionamide and prothionamide are now included in group C of the WHO recommended drugs for the treatment of tuberculosis resistant to rifampicin and multidrug-resistant tuberculosis. The clinical relevance of ethionamide and prothionamide has increased with the wide spread of resistant tuberculosis. Methods: We retrospectively analyzed 349 clinical isolates obtained between 2016 and 2020. The susceptibility to ethionamide was tested using both the BactecTM MGITTM 960 system and the SensititreTM MYCOTB plate. Results: The MIC of ethionamide increases with the total resistance of the isolates in a row from susceptible to XDR strains. A significant part of the isolates have a MIC below the breakpoint: 25%, 36%, and 50% for XDR, pre-XDR, and MDR strains. Sensitivity and specificity of detection of mutations were 96% and 86% using MGIT resistance as a reference. Conclusions: Phenotypic methods for testing ethionamide are imperfectly correlated, and the isolates with MIC of 5 mg/L have the intermediate resistance. A significant proportion of resistant TB cases are susceptible and eligible for ethionamide treatment. Resistance could be explained using only analysis of loci ethA, PfabG1, and inhA for most isolates in the Moscow region. The promoter mutation PfabG1 c(-15)t predicts resistance to ethionamide with high specificity but low sensitivity.

31 March 2013 in Plasmid
Verified
Journal Article
Closed access
ASAndrey N Shkoporov
Andrey N Shkoporov
EKEkaterina V. Khokhlova
Ekaterina V. Khokhlova
EKElena Kulagina
Elena Kulagina
VSVladimir V. Smeianov
Vladimir V. Smeianov
AKAnna Kuchmiy
Anna Kuchmiy
BEBoris A. Efimov
Boris A. Efimov

Verified
Journal Article
Open access
PDF file
ESElena Savvateeva
Elena Savvateeva
Marina YukinaMarina Yukina
Marina Yukina
NNNurana Nuralieva
Nurana Nuralieva
SBSvetlana Bykova
Svetlana Bykova
IAIvan S. Abramov
Ivan S. Abramov
Dmitry GryadunovDmitry Gryadunov
Dmitry Gryadunov
This study investigated the IgA antibodies targeting bovine serum albumin (BSA) in 27 adult celiac disease (CD) patients adhering to a gluten-free diet (GFD), compared to 123 controls (including individuals with autoimmune disorders, those with gastrointestinal cancers, and healthy donors). Serum samples were evaluated using a multiplex assay based on a microarray comprising 66 immobilized antigens, including autoantigens associated with autoimmune diseases, different albumins, cytokines, and inflammatory markers. Elevated IgA-BSA levels were detected in 22% of CD patients versus 3.25% of controls. IgA-BSA did not cross-react with milk proteins like casein, β-lactoglobulin, and γ-globulin, nor with autoantigens and human albumin, ruling out autoimmunity against self-proteins. The observed cross-reactivity with porcine albumin suggests that antibodies target epitopes shared by bovine and porcine albumin. Increased IgA-BSA levels may interfere with immunoassays performed using BSA as a stabilizer, necessitating protein-free buffers to avoid false results when testing CD patients. Elevated IgA-BSA levels may reflect ongoing gut barrier dysfunction in CD patients on a GFD, allowing dietary proteins like BSA to trigger immune responses. This study identifies a novel immune response in CD patients on a GFD, emphasizing the need for tailored diagnostic approaches (BSA-free assays) and further research into the clinical and dietary implications of IgA-BSA elevation.

31 January 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
ESElena Savvateeva
Elena Savvateeva
VSVera Sokolova
Vera Sokolova
Marina YukinaMarina Yukina
Marina Yukina
NNNurana Nuralieva
Nurana Nuralieva
EKElena Kulagina
Elena Kulagina
Dmitry GryadunovDmitry Gryadunov
Dmitry Gryadunov
Background/Objectives: The aim of this study was to evaluate the avidity of thyroid autoantibodies (Abs) in sera of patients with autoimmune thyroid disease (AITD) and thyroid autoantibody carriers without diagnosed AITD. Methods: A hydrogel microarray-based multiplex assay with the chaotrope destruction stage was developed to measure the avidity of thyroid disease-associated autoantibodies, including those targeting thyroperoxidase (TPO), thyroglobulin (Tg), and other minor antigens. Results: Evaluation of the assay in three independent cohorts of patients, totaling 266 individuals with and without AITD, demonstrated the heterogeneous avidity of autoantibodies to thyroid proteins. For the confirmation study, the median avidity index (AI) for AbTg was 29.9% in healthy autoantibody carriers, 52.6% for AITD patients, and 92.7% for type 1 diabetes (T1D) thyroid autoantibody carriers. The median AI for AbTPO was 39.9% in healthy carriers, 73.4% in AITD patients, 83.2% in T1D thyroid autoantibody carriers, and 98.5% in AITD patients with thyroid neoplasm. In patients with Hashimoto’s thyroiditis and known disease duration, changes in the avidity maturation of AbTPO over time were demonstrated. Conclusions: Longitudinal studies of TPO- and/or Tg-positive healthy individuals (with an interval of 1–2 years between visits) are needed to evaluate the maturation of autoantibody avidity during the asymptomatic phase and to assess the potential of autoantibody avidity as a prognostic marker for disease development.